Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms
← catalyst calendarNCT07684170 · readout ≤ 773 d
Sponsored by Compass Therapeutics (industry) · CMPX — their whole pipeline →.
Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
58estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Sep 2026 | estimated | When the study began enrolling |
| Primary completion | Sep 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Neuroendocrine Neoplasm
- Neuroendocrine Carcinomas
- Neuroendocrine Tumors
Intervention
- Drug: CTX-471
Primary outcomes
what the primary-completion date above is the date OFEvaluate the clinical activity of CTX-471
measured Baseline until confirmed disease progression (up to 1 year)
Evaluate the safety of CTX-471
measured From first dose of CTX-471 (Cycle 1 Day 1, Cycle = 2 weeks) until 30 days after the last dose of CTX-471
Determine the recommended phase 2 dose (RP2D) for CTX-471
measured From first dose of CTX-471 (Cycle 1 Day 1, Cycle = 2 weeks) until 30 days after the last dose of CTX-471
Permalink · CMPX's whole pipeline · Catalyst calendar · Every registered study · What changed